Dr. Feng Lin, a distinguished medical doctor specializing in hematophysiology, brings nearly 20 years of experience from prestigious research institutions and the biotech industry in the United States. His innovative projects have led to several successful clinical applications.

Current Role:

Dr. Lin currently leads a team focused on precision medicine and personalized therapy development. His work involves genetic sequencing (whole exome sequencing/WES and RNA), metabolomics, and proteomics analysis of tumor samples and peripheral blood cells from cancer patients. Utilizing machine learning and AI models, his team assesses patient sensitivity to chemotherapy and radiotherapy, identifies neoantigen targets, and designs personalized neoantigen vaccines and TCR-T therapies for individualized treatment.

Previous Experience:

• At Sanford Burnham Prebys Medical Discovery Institute, Dr. Lin conducted groundbreaking research on cancer pathogenesis.
• At Inovio Pharmaceuticals, he developed DNA delivery technology and therapeutic vaccines, including an HPV DNA-based cervical cancer vaccine that advanced to phase 3 clinical trials and secured a $24 million deal for greater China rights.
• As the China Operations Director at MediStem, he developed a rapid clinical translation model that facilitated FDA approval and subsequent acquisition by Intrexon in May 2014.
• Dr. Lin has also held positions as Technical Director at Superview Biotechnology Co Ltd and Batu Biologics, and as Principal Investigator at CureScience Institute.

Achievements:

Published 30 research papers and holds 15 patents.

Dr. Lin's extensive expertise and leadership in precision medicine and cancer research continue to drive significant advancements in the field, contributing to improved therapeutic strategies and patient outcomes.